fda

FDA Approves UAB Medical Marijuana Study

/in , /by

The US Food and Drug Administration (FDA) has given the University of Alabama at Birmingham (UAB) the green light to study the use of a marijuana derivative to treat seizures.

On Wednesday, UAB received an approval letter from the agency, allowing for studies that would focus on the health effects of cannabidiol, or CBD. The FDA authorized two studies evaluating CBD for seizures, one of which will be conducted in children and the other in adults. The approval from the federal agent was welcoming news for families who had pushed to make CBD oil legally available in the state.

According to Bob Shepard, a UAB spokesman, the letter did ask for some modifications to the protocols employed. However, Shepard said that the changes are minor, and mostly in some of the language and information provided to patients.

In April, the Alabama Legislature approved $1 million for the study, as well as a bill called “Carly’s Law,” protecting those who participate in the program from criminal prosecution. The law was named after Carly Chandler, a three-year old with a rare genetic disorder that causes her to have up to 200 seizures a day. Carly’s father and police officer Dustin Chandler spoke to incoming state representatives on Tuesday at House Speaker Mike Hubbard’s invitation, telling them that he believed their efforts were giving parents around the state hope.

UAB officials must now go before the UAB Institutional Review Board in January, and the university must also get permission from the US Drug Enforcement Administration.

Last updated: 12/11/14; 3:05pm EST

AES

New Studies Evaluate Cannabis Treatment in Epilepsy Patients

/in /by

Studies presented at the American Epilepsy Society’s (AES) 68th Annual Meeting offer new insights into diverse patients’ experience with cannabidiol (CBD) for treatment of patients with various forms of epilepsy.

Although there have been many anecdotal reports regarding cannabis and its derivative CBD in the treatment of people with epilepsy, especially in very young children who severe forms of epilepsy, such as Lennox Gastaut Syndrome (LGS) or Dravet Syndrome (DS), there is little scientific evidence regarding its efficacy in this patient population. At the AES Annual Meeting, three new studies focused on the use of cannabis in epilepsy were featured to offer new insights.

The first of three studies is from Colorado, where marijuana is legal for both medical and recreational use. The physicians and researchers at Children’s Hospital Colorado and the University of Colorado have a unique perspective on CBD, due to the large number of cases they have treated. In addition to the children already in their care, these professionals are now caring for several patients who have moved to the state in order to receive cannabis treatment.

Dr. Kevin Chapman, associate professor of pediatrics and neurology at the University of Colorado, and his team conducted a retrospective review of 58 children and adolescents with catastrophic forms of epilepsy who were receiving artisanal oral cannabis extracts when they came under their care. The average age of the subjects was seven. The researchers found that in only one-third of patients did the parents report a seizure reduction of 50 percent or more, and this did not correlate with an improvement in their electroencephalograms (EEGs). Of the 16 patients who had baseline EEGs prior to and during treatment with cannabis, only two demonstrated signs of improvement. According to the researchers, the response rate did not change with various strains of cannabis. The researchers noted that families who moved to Colorado specifically for CBD treatment were three times more likely to report a reduction greater than 50 percent than families who were already in the state.

“This substantial gap between the clinical observations and various anecdotal reports highlighted in popular media underscores the desperate need shared by the entire epilepsy community for robust scientific evidence regarding the potential benefit and risks of marijuana in people with epilepsy,” said Dr. Chapman.

The second study documents the experienced reported by parents of children with infantile spasms (IS) or LGS who were treated with artisanal CBD-enriched cannabis preparations. A UCLA based research team surveyed 53 parents who had children with IS and/or LGS. The team found that among those surveyed, 92 percent of parents reported a reduction in seizures and 13 percent reported complete seizure-freedom. The majority of responders reported using a CBD preparation with a CBD:THC ration of at least 15:1. The median age of the children was 3.6 years. Prior to starting CBD, the parents reported that their children had typically tried and failed 8 medications prior to CBD. Most patients with IS had failed hormonal therapy and vagabtrin, with a median length of other therapy of 6.9 months. Respondents reported that side effects of treatment were also less than those with other medication. Benefits reported included improvement in sleep, alertness and mood during treatment with CBD.

“Although this study suggests a potential role for CBD in the treatment of IS and LGS, it is important to note that this study does not represent compelling evidence of efficacy or safety,” said Raymond Zhou, research associate, UCLA Infantile Spasms Project. “From a methodological standpoint, this study is extraordinarily vulnerable to participation bias and placebo effect as our data is self-reported by parents and did not use objective measures such as EEG. Our hope in presenting this data is to emphasize the need for controlled clinical trials to establish safety and efficacy.”

The third study is a single case of a child with Doose Syndrome whose family initiated independent CBD treatment. A four-year old experiencing several seizure types tried various medications and with various and limited benefits. Baseline video EEG showed that the child experienced at least ten seizures per day while awake and asleep. Immediately after initiating CBD, the child continued to have seizures and Valproic acid levels increased substantially. When the dosage of Valproic acid was reduced the blood level returned to the previous range, and over four months seizures disappeared clinically and a repeat EEG was normal in both awake and asleep periods.

“We cannot recommend CBD treatment based on the limited evidence at this time, but do hope that families who independently seek CBD treatment will continue conventional therapies and remain in close contact with their healthcare providers,” said Jeffrey Gold, MD, PhD, Rady Children’s Hospital of San Diego. “Establishing EEG measures before and after CBD treatment will provide the best possible insight into the benefits of the treatment. Further, since the effect of CBD treatment on other medications is undetermined, we recommend that physicians work with families to determine if adjustments to other medications are necessary.”

Source: American Epilepsy Society

Last updated: 12/11/14; 12:05pm EST

DEA

Spending Bill Prevents Funding for Medical Marijuana Raids

/in /by

A federal spending bill released late Tuesday includes an amendment that would prevent the Department of Justice (DOJ) from using any funds to undermine state medical marijuana laws.

The spending bill also includes a bipartisan amendment that prohibits the Drug Enforcement Administration (DEA) from blocking implementation of a federal law that allows hemp cultivation for academic and agricultural purposes in states that allow it.

The Rohrabacher-Farr amendment was introduced and approved earlier in May by the House and is included in the 1,603-page spending bill. The bill will prevent the DOJ and DEA from targeting patients and providers in the more than 20 states with some form of medical marijuana program.

“This is a great day for patients and for public safety,” said Major Neil Franklin (Ret.), executive director of Law Enforcement Against Prohibition. “Congress has finally listened to the vast majority of Americans who believe the federal government has no right to interfere in the personal decision to use medical marijuana made by a patient in consultation with his or her doctor. Law enforcement never should have been a part of that decision and if this amendment passes, they no longer will.”

However, the bill also includes a provision that could block Washington, DC from implementing an initiative to legalize marijuana, which voters approved in November by a margin of 70 percent to 30 percent. It is still unclear how the passing of this bill would affect the measure to legalize small amounts of marijuana for personal use in DC, but the Drug Policy Alliance said that it urges the DC Council to side with voters and transmit the initiative to Congress regardless.

Before the bill becomes law, it must be approved by the full House and Senate and then signed into law by President Obama. The congressional votes are expected later this week.

Last updated: 12/11/14; 10:25am EST

GW Pharma

GW Pharma Considered a Reputable Cannabis Company to Invest in

/in /by

With a major expansion in companies entering the cannabis market, it is difficult to identify reputable companies to invest in.

Earlier this year, the SEC issued warnings of marijuana-related penny stocks proliferating after cannabis legalization became a reality in Colorado, Washington, Oregon and the District of Columbia. The SEC defines penny stocks as “a very small company that trades at less than $5 per share.”

While investing in cannabis companies in the US remains highly speculative, investing in reputable companies, such as GW Pharmaceuticals may produce significant returns.

GW recently released Q4 2014 results, which led to a ten percent spike in share price, mainly because of non-GAAP earnings of $0.20 per share beat mean consensus estimates of -$0.69. GW’s cannabinoid-based drug Sativex is approved for the treatment of spasticity due to multiple sclerosis (MS) in 27 countries outside of the US. The drug is also in Phase III clinical development as a potential treatment of pain associated with advanced cancer. The Phase III program is intended to support filing a New Drug Application (NDA) for the drug in cancer pain with the US Food and Drug Administration (FDA), and in other markets around the world.

GW’s CEO Justin Gover highlighted the company’s transformation, primarily resulting from the rapid advance of its Epidiolex program over the last year. The drug has brought in significant capital from investors for its potential in treating Dravet syndrome, Lennox-Gastaut syndrome and other forms of childhood epilepsy.

The companies have reported net cash proceeds of $212 million and a cash balance at the end of the fiscal year of $267 million for use in future commercial development. The company did report a loss for the year under review, however this is common among young biotech companies.  GW said that its net cash outflow will increase again next year, with the development of manufacturing capacity and testing for Epidiolex and Sativex. The company anticipates that this will decrease significantly and revenues are will increase once products come to market in 2016.

In addition to Sativex and Epidiolex, GW has 20 other cannabinoid drugs in development for a variety of ailments including Glioblastoma Multiforme (GBM), Type 2 diabetes, schizophrenia and ulcerative colitis.

Insys Therapeutics is another reputable company in the cannabis market. The US-based specialty pharmaceutical company has two marketed products, Subsys and Dronabinol SG Capsule, which leverage the company’s sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. Its Subsys is approved for the treatment of cancer pain, and provides the company with cash flow. However, Insys has fewer drugs in the pipeline than GW and fewer international approvals.

Companies traded on the over the counter market may have some drawbacks. In May, the SEC issued temporary trading suspensions for the common stock of cannabis companies including FusionPharma, Inc., Cannabusiness Group, Inc., GrowLife, Inc., Advanced Cannabis Solutions, Inc., and Petrotech Oil and Gas, Inc. The SEC suspended trading in these companies due to questions regarding the accuracy of publicly-available information about these companies’ operations. Additionally, in two of these companies, the trading suspensions were also based on potential illegal activity, such as unlawful sales of securities and market manipulation.

Sources: GW Pharmaceuticals plc; Insys Therapeutics, Inc.; Securities and Exchange Commission

CannaPharmaRx logo

CannaPharmaRx, Inc. Announces New Financial Controller to Be Based in NJ Headquarters

/in /by

CARNEY’S POINT, NJ–(Marketwired – December 05, 2014) – CannaPharmaRx, Inc., (OTCQB: GDHC), the New Jersey-based pharmaceutical research and discovery company, today announced the hiring of Thomas J. Della-Franco III as Financial Controller. Mr. Della-Franco will work on a consulting basis out of the company’s new headquarters in Carney’s Point, New Jersey.

“Tom’s diverse work experience is an excellent fit for our rapidly evolving company. He is a highly accomplished financial executive with expertise in manufacturing, importing and distribution, and with demonstrated success in financing, refinancing, restructurings and mergers & acquisitions,” said Gerry Crocker, CEO, CannaPharmaRx.

In his most recent position as Chief Financial Officer for ZPC Holdings, Mr. Della-Franco led the company’s Sarbanes Oxley (SOX) compliance, strategic acquisitions, LBOs, private equity rounds and was the key contact for due diligence rounds prior to the company’s sale to a Fortune 500 company. Prior to ZPC Holdings, Mr. Della-Franco worked as Senior Auditor for the auditing firm of Peat, Marwick Mitchell & Company (now KPMG) in Philadelphia.

“For me, the most rewarding position is one where I can have a balance of strategic and hands-on financial management. At CannaPharmaRx, I am looking forward to helping to identify and capture opportunities to help the company accelerate, expand and grow,” said Mr. Della-Franco.

This week, CannaPharmaRx officially announced the opening of its New Jersey headquarters where its administrative offices, including finance, are now based. Financial information can be found in the company’s form 10-Q filing for the fiscal third quarter ending September 30 which was filed with the Securities and Exchange Commission on November 19.

 

About CannaPharmaRx: Headquartered in Carney’s Point, New Jersey, CannaPharmaRx is a pharmaceutical company whose mission is to advance cannabinoid discovery, science, research & development, and to bring novel prescription, veterinary and personal care cannabinoid-based products to market in the U.S. and worldwide. For more information, visit www.cannapharmarx.com.

Forward Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on CannaPharmaRx’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful.

CannaPharmaRx does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx’s private placement agreement and Form 10-Q as of September 30, 2014 (Unaudited) and other periodic reports filed with the Securities and Exchange Commission.

 

Insys Therapeutics

Analyses Show Insys’ Synthetic CBD is Chemically Identical to the Plant-Derived CBD

/in , , /by

Specialty pharmaceutical company, Insys Therapeutics, Inc. recently announced that analyses determined that its synthetic cannabidiol (CBD) is chemically identical to the plant-derived CBD.

The determination was made by comparison analyses, which were conducted independently by Insys and the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). In order to conduct the comparison analyses, both Insys and NIDA utilized NIDA-supplied natural, plant-derived CBD and synthetically produced CBD supplied by Insys.

The two separately-conducted analyses ascertained that Insys’ synthetically produced CBD:

  • Has identical identity and chemical structure to plant-derived CBD;
  • Has identical stereochemistry to plant-derived CBD, with both demonstrating the same (-) CBD enantiomer with no (+) enantiomer present, which was confirmed by Chiral Assay;
  • Is more pure, with a two percent higher CBD Assay value than plant-derived CBD;
  • Insys CBD total HPLC purity 99.9 percent vs. plant-derived CBD at 98.7 percent; and,
  • Meets all ICH impurity guidelines, with no impurities greater than 0.10 percent, vs. plant-derived CBD which contained multiple impurities above ICH guidelines.

“These results of NIDA’s analyses confirm those conducted in our laboratories, demonstrating that our CBD is identical in chemical structure to plant-derived CBD as determined by multiple methods,” said Michael L. Babich, President and Chief Executive Officer of Insys. “We believe our product’s purity levels will provide consistent material for our clinical programs, including our program to evaluate CBD in pediatric patients suffering from Dravet Syndrome and Lennox-Gastaut Syndrome. We plan to dose our first human subjects in the first quarter of 2015 in a Phase I setting.”

Insys’ synthetic, pharmaceutical CBD is produced under cGMP conditions at its FDA-inspected and Drug Enforcement Administration (DEA)-approved facility in Round Rock, Texas. The company said that its facility allows for manufacturing CBD at greater batch-to-batch consistency and uniformity. The company believes that it is the only US-based company that is capable of producing pharmaceutical cannabinoids in scalable quantities.

Insys has been approved as a qualified supplier of CBD to NIDA, and NIDA will refer CBD requests directly to Insys.

Source: Insys Therapeutics, Inc.

Last updated: 12/9/14; 2:00pm EST

 

cannabis science

Cannabis Science Joins Constituency for Africa to Improve Africa’s Healthcare Infrastructure

/in /by

Cannabis Science, Inc. announced that it has joined forces with the Constituency for Africa (CFA) to focus on improving the healthcare and health-related education structure in Africa.

Cannabis Science’s President & CEO Raymond C. Dabney and Senior Scientific Advisor Dr. Roscoe M. Moore, Jr. have initiated a partnership between Cannabis Science and CFA to help improve the healthcare infrastructure as part of CFA’s 2015 strategy.

CFA, a Washington-based education and advocacy organization, was founded in 1990. Currently in its 25th year of operation, the organization has emerged as a leader in mobilizing public and private support for Africa in Washington, DC. The CFA plans on launching this African healthcare infrastructure initiative in February of next year, with a stakeholders’ forum in Washington. The forum will bring together senior officials and leaders in the African Union and African Diplomatic Corps, Obama Administration, Congress, World Bank, private sector, and the Diaspora. The effort will be led by a high-level advisory committee of experts, with a goal of dramatically improving the healthcare infrastructure across the African Continent.

Cannabis Science’s President & CEO will also serve as a co-chair of this new CFA Health Roundtable. Cannabis Science’s expertise in cannabinoid research will be used with the CFA’s multiple strengths and relationships to help further the cause in Africa of treating diseases and symptoms of diseases including cancer, relief from severe pain and some AIDS-related illnesses.

“The CFA enjoys direct access to a number of the key opinion leaders from African leaders to U.S. lawmakers to international development organizations. Most importantly, the CFA is highly connected to a range of Diaspora leaders and experts in healthcare and other fields, who have much to offer in the effort to help Africa. We can effectively bring these voices together to generate the needed momentum and investment to dramatically improve the healthcare infrastructure over the coming years,” said Dr. Moore.

According to the CFA’s President and CEO Melvin Foote, the launch of this initiative is timely and needed, with the Ebola epidemic serving as a “wake-up call.” Since the summer, more than 6,000 people in Liberia, Sierra Leone and Guinea have died from Ebola, leaving a devastating effect on the economies of these countries, as well as other affected countries in the region. The Ebola crisis has caused schools to close and hospitals to become non-functional, demonstrating an urgent need for a much improved health infrastructure in the region and across Africa.

“The Ebola epidemic has been a tremendous wake-up call about the weak state of healthcare infrastructure in the countries strickened by the disease, particularly in the midst of the AIDS crisis. As Ebola rapidly spread to a number of countries in and outside of Africa, the entire world has finally realized that we are all at risk if we continue to ignore the plight of people in Africa, as any disease is only a plan ride away. We are extremely welcoming of Mr. Dabney and Cannabis Science’s aggressive leadership,” said Mr. Foote.

Source: Cannabis Science, Inc.

Last updated: 12/9/14; 10:10am EST

Sue Sisley

Former UA Professor Nominated for a $2 Million Grant to Study Marijuana’s Effects in Veterans with PTSD

/in , /by

The state of Colorado nominated providing a $2 million grant to a fired University of Arizona professor to continue her research in marijuana’s effects on veterans with post-traumatic stress disorder (PTSD).

Dr. Sue Sisley was controversially fired from her teaching position at the University of Arizona earlier this year. Although UA officials said in a letter that Sisley was let go because funding for part of the work she did with the medical school was running out and other factors, Sisley claimed that her termination was a result of pressure put on the school by Republican politicians in the state legislature.

The grant is awaiting approval from the Colorado Board of Health, who is scheduled to make a decision on December 17th.  The Colorado State Medical Marijuana Scientific Advisory Council recommended eight studies, worth $7.5 million in funding, to be financed from a $10 million fund the General Assembly set aside last year for medical marijuana research.

Sisley said that the study, which will consist of 76 veterans suffering from PTSD, will be split between participating veterans in Arizona and at the Johns Hopkins University in Baltimore.  The grant would allow her to carry out the triple-blind study within one year.

However, even if Sisley receives the grant, she will still need access to marijuana. In March, Sisley received approval to conduct the study from the National Institute of Drug Abuse (NIDA), the only organization that can provide researchers with marijuana needed to conduct studies. However, she has yet to receive any resources to conduct her study.

Sisley first teamed up to study marijuana’s effects on PTSD with the Multidisciplinary Association for Psychedelic Studies (MAPS) five years ago. According to MAPS, there are an estimated 7.7 million Americans living with PTSD. Additionally, according to the Department of Veterans Affairs, 22 soldiers commit suicide each day. The research, conducted by Sisley and sponsored by MAPS, could provide a scientific basis for a new treatment for the condition for veterans, as well as individuals living with PTSD.

Source: Multidisciplinary Association for Psychedelic Studies

Last updated: 12/2/14; 3:00pm EST

Nuvilex

Nuvilex Gains Exclusive Worldwide License to Develop Treatments Combining Cell-in-a-Box and Cannabinoid-Based Meds

/in , /by

Clinical-stage biotechnology company, Nuvilex, Inc., has obtained an exclusive worldwide license to develop disease treatments by combining Cell-in-a-Box with cannabinoids.

The company obtained the license from Austrianova Singapore Pte Ltd to use the unique proprietary Cell-in-a-Box cellulose-based live cell encapsulation technology in combination with cannabinoid compounds, obtained from constituents of Cannabis. Nuvilex said that its initial efforts will be directed toward developing treatments for deadly and difficult-to-treat cancers.

“While our efforts in the medical Cannabis arena have been ongoing for some time now, this exciting worldwide Licensing Agreement enabling the use of Cell-in-a-Box® with cannabinoid prodrugs will greatly enhance our effort to become a major player in the medicinal cannabinoid space. This is truly a collaborative agreement which is designed to capitalize on the ever-increasing body of evidence indicating constituents from the Cannabis plant indeed have a place in the treatment of serious and even deadly forms of cancer,” said Kenneth L. Waggoner, CEO and President of Nuvilex.

Combining Cell-in-a-Box live cell encapsulation technology with prodrugs for treatment of serious cancers has already been validated in human clinical trials in patients with advanced, inoperable pancreatic cancer and in a veterinary preclinical trial in dogs with spontaneously-occurring mammary cancer. In both cases, the cells encapsulated were designed to overexpress an enzyme known as CYP2B1, an isoform of the cytochrome P450 system, normally found in the liver. In the clinical trials involving pancreatic cancer patients, the prodrug used was ifosfamide, and its sister drug cyclophosphamide was used in the canine mammary cancer preclinical trial. Both prodrugs were converted to their cancer-killing forms by CYP2B1 and have shown positive results.

“Over the course of the last year, we have worked very closely with Nuvilex to secure the exclusive worldwide rights to use our Cell-in-a-Box® technology for the development of cannabinoid-based disease treatments. We’re excited about the opportunity to collaborate with them to further the science in this exciting medical field where the possibility exists of treating cancers and other diseases without the harmful side effects normally associated with their treatment,” said Dr. Brian Salmons, CEO and President of Austrianova and a member of the Scientific Advisory Board of Medical Marijuana Sciences, a wholly-owned subsidiary of Nuvilex.

Prof. Walter H. Günzburg, Chairman and CTO of Austrianova, said, “It is well documented in scientific and medical journals that cannabinoid-based drugs have a therapeutic benefit in cancer but the ability to administer these drugs at a therapeutic level is challenging. The use of encapsulated cells to convert prodrugs as pioneered by Austrianova and Nuvilex is a viable alternative. We are delighted to have signed the Licensing Agreement as part of the ongoing efforts towards this aim.”

Using the Cell-in-a-Box technology should optimize the anticancer effect of the cannabinoid prodrugs, while minimizing deleterious side effects that are associated with chemotherapy.

Source: Nuvilex, Inc.

Last updated: 12/2/14; 2:05pm EST

GW

GW Pharmaceuticals Reports Increased Spend on R&D in 2014

/in , /by

Today, GW Pharmaceuticals plc announced financial results for the fourth quarter and year ended September 30, 2014.

The company said that total revenue for the year was only slightly up at £30 million compared to £27.3 million the year before. However, net loss after tax more than tripled to £14.7 million from £4.5 million in 2013. GW’s Chief Executive Officer Justin Gover said that this was primarily due to the increased investment in research and development (R&D) in 2014.

GW’s cannabinoid prescription drug, Sativex, is approved in 27 countries outside of the US for the treatment of spasticity due to multiple sclerosis (MS). The drug is also in late-stage development for treatment of pain linked to advanced cancer.

The company’s Epidiolex program for childhood epilepsy had advanced rapidly in the last year. The drug is currently in clinical trials for treatment of Dravet syndrome and Lennox-Gastaut syndrome (LGS)

“GW’s business has transformed over the last year principally as a result of the rapid advance of our Epidiolex program to treat orphan syndromes in the field of childhood epilepsy. During 2014, we have raised significant capital from U.S. investors, commenced treatment of approximately 200 children, obtained encouraging clinical data, and commenced formal clinical development in the U.S.,” said Gover. “In 2015, we expect to complete much of the Epidiolex development program as well as start to build a U.S. commercial presence in anticipation of future launch. Beyond Epidiolex, we expect to report Phase 3 data from the Sativex cancer trials in early 2015 which, if positive, would enable the filing of NDA in the U.S. during next year. We also look forward to progressing multiple clinical trials for our cannabinoid product pipeline.”

GW is also developing GWP42006 as a treatment for patients with epilepsy. The company is also testing its product candidate GWP42002:GWP42003 in the treatment of recurrent glioblastoma multiforme (GBM), an aggressive brain tumor which is considered a rare disease by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, GW is testing its GWP42003 in patients with ulcerative colitis and schizophrenia, and its GW42004 in patients with type 2 diabetes.

Source: GW Pharmaceuticals plc

Last updated: 12/2/14; 12:10pm EST